2022-07-25 16:12
An exclusive interview with Professor Huang Jing | Pucotenlimab has been approved, which brings a new treatment option for MSI-H/dMMR advanced solid tumors!
Introduction:
The incidence of microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) in patients with solid tumors is approximately 10%-22% [1], with a higher incidence for c...
More